11:20:32 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-08-30 Kvartalsrapport 2024-Q2
2024-06-01 Kvartalsrapport 2024-Q1
2024-05-30 Årsstämma 2024
2024-04-22 X-dag ordinarie utdelning DANCAN 0.00 DKK
2024-04-17 Extra Bolagsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-04-19 X-dag ordinarie utdelning DANCAN 0.00 DKK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-04 Kvartalsrapport 2022-Q3
2022-09-20 Extra Bolagsstämma 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-04-08 X-dag ordinarie utdelning DANCAN 0.00 DKK
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-23 Extra Bolagsstämma 2021
2021-05-28 Kvartalsrapport 2021-Q1
2021-04-29 X-dag ordinarie utdelning DANCAN 0.00 DKK
2021-04-28 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020


ListaSpotlight DK
IndustriLäkemedel & Handel
DanCann Pharma grundades 2018 och är ett danskt läkemedelsbolag. DanCann Pharma fokuserar på att upptäcka, utveckla, tillverka och kommersialisera nya cannabinoida läkemedel inom ett brett spektrum av sjukdomsområden. Bolaget tillverkar och distribuerar receptbelagda läkemedel och receptfria läkemedel (OTC), främst fokuserade på smärtpatienter med alternativa behov och hantering av sin sjukdom, täckta av det danska pilotprogrammet för medicinsk cannabis.
2022-05-18 17:00:00

COPENHAGEN, Denmark, 18 May 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the first quarter of 2022. The Q1-2022 report is available as an attached document to this press release and at www.dancann.com.

Group key figures Q1-2022:

KDKK 01/01/22 01/01/21 01/01/21 01/01/20
31/03/22 31/03/21 31/12/21 31/12/20
Net sales 1,266 0 874 0
Operating profit (EBIT) -3,549 -2,591 -14,509 -5,870
Result per share (DKK) -0.01 -0.09 -0.52 -0.48
Equity ratio 0.80 0.90 0.78 0.89

Number of shares on 31.03.22: 28.468.289 (20.730.800)
Result per share = Result for the period / weighted average number of shares
Equity ratio = Equity / Total assets

DanCann Pharma has significantly upgraded with key people both in the organization and in the Board of Directors and aim to be able to have a top professional approach and mindset overall. At Biotech Pharm1 - the Company's production facilities - tests and analysis show that it is possible to produce biomaterial with a high content of THC and free of contaminants. Highly promising results.     

The subsidiary CannGros, which DanCann Pharma acquired in October 2021, is well underway in the process of being integrated into DanCann Pharma. The level of ambition is high from the executive management team, both in terms of maintaining CannGros' strong market position and to fully utilize the great development potential of the subsidiary.

Jeppe Krog Rasmussen, CEO of DanCann Pharma, comments:

- During this period, DanCann Pharma is undergoing a change from being an ambitious project to a growth company in operation. In the past year, we have significantly equipped ourselves with key people both in the organization and on the Board of Directors, and we aim to be able to have a top professional approach to everything we do. This is what our many investors expect, who loyally support and show great confidence in our development potential.

- Soon we will face our biggest milestone so far, when the first batch of self-produced biomaterial must be ready for delivery to selected export markets. At the same time, our subsidiary CannGros must be integrated into DanCann Pharma and the level of ambition is high. Both in terms of maintaining CannGros' strong market position and in order to fully utilize the company's great development potential.

- The acquisition of CannGros has meant that DanCann Pharma has been able to add the desired commercial unit, and we must jointly develop and strengthen this, because CannGros has proven to be a really strong acquisition and an important addition to our Company. The acquisition has enabled us to enter the market significantly faster by purchasing an already existing platform and everything that belongs here, such as know-how, products, pipeline and an established quality system.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com


Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.